Pulmonx (LUNG) Competitors

Pulmonx (NASDAQ:LUNG) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking.

Which has better earnings & valuation, LUNG or ESTA?

Pulmonx has higher earnings, but lower revenue than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$68.68M	3.50	-$60.84M	-$1.47	-4.14
Establishment Labs	$165.15M	5.82	-$78.50M	-$2.58	-13.29

Does the media favor LUNG or ESTA?

In the previous week, Pulmonx had 3 more articles in the media than Establishment Labs. MarketBeat recorded 5 mentions for Pulmonx and 2 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.71 beat Pulmonx's score of 0.60 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Establishment Labs	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer LUNG or ESTA?

Establishment Labs received 84 more outperform votes than Pulmonx when rated by MarketBeat users. Likewise, 61.90% of users gave Establishment Labs an outperform vote while only 44.00% of users gave Pulmonx an outperform vote.

Company	Underperform	Outperform
Pulmonx	Outperform Votes 33 44.00%	Underperform Votes 42 56.00%
Establishment Labs	Outperform Votes 117 61.90%	Underperform Votes 72 38.10%

Which has more risk & volatility, LUNG or ESTA?

Pulmonx has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Establishment Labs has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.

Do analysts prefer LUNG or ESTA?

Pulmonx currently has a consensus price target of $12.75, suggesting a potential upside of 109.70%. Establishment Labs has a consensus price target of $60.60, suggesting a potential upside of 76.68%. Given Pulmonx's higher possible upside, equities research analysts plainly believe Pulmonx is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Establishment Labs	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do insiders & institutionals believe in LUNG or ESTA?

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 72.9% of Establishment Labs shares are owned by institutional investors. 5.7% of Pulmonx shares are owned by company insiders. Comparatively, 11.4% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is LUNG or ESTA more profitable?

Establishment Labs has a net margin of -46.13% compared to Pulmonx's net margin of -72.01%. Pulmonx's return on equity of -53.88% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-72.01%	-53.88%	-33.47%
Establishment Labs	-46.13%	-184.55%	-24.81%

Summary

Establishment Labs beats Pulmonx on 11 of the 19 factors compared between the two stocks.